TheraP Trial

177Lu-PSMA-617 Theranostics Might Be More Active and Safer than Cabazitaxel 

177Lu-PSMA-617 Theranostics Might Be More Active and Safer than Cabazitaxel 

The trial showed that the LuPSMA treatment delayed prostate cancer progression versus Jevtana, with a comparable benefit observed in radiographic progression-free survival and PSA progression-free survival.